To address this gap, we retrospectively analyzed the metastatic HER2‐positive GC patients treated by the combination of checkpoint inhibitor, chemotherapy, and trastuzumab between 2019 and 2022 in our institution in a real‐world setting. The gene discussed is ERBB2; the disease is gastric cancer.